Skip to main content
Mikhail Kosiborod, MD, Cardiology, Kansas City, MO, Saint Luke's East Hospital

MikhailKosiborodMD

Cardiology Kansas City, MO

Echocardiography, Preventive Cardiology

Professor of Medicine (Cardiology), Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City School of Medicine

Dr. Kosiborod is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kosiborod's full profile

Already have an account?

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Cardiovascular Disease, 2001 - 2004
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 1997 - 2001
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 1997

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 2005 - 2025
  • KS State Medical License
    KS State Medical License 2005 - 2024
  • CT State Medical License
    CT State Medical License 2000 - 2006
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients with Heart Failure with Reduced Ejection Fraction  
    Mikhail N Kosiborod, Marc S Sabatine, JAMA Cardiology
  • Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients with Heart Failure with and Without Diabetes  
    Akshay S Desai, Mikhail N Kosiborod, Marc S Sabatine, JAMA
  • Real‐World Opportunity of Empagliflozin to Improve Blood Pressure Control in African Americans with Type 2 Diabetes: An NCDR® “Research‐to‐Practice” Project from the D...  
    Suzanne V Arnold, Mikhail Kosiborod, Diabetes, Obesity and Metabolism
  • Join now to see all

Lectures

  • Drug Choices in Diabetes and Heart Failure Advice for the Practicing Cardiologist 
    2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
  • Summary of the ACC Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Diabetes 
    2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
  • Changing Paradigm in Cardiovascular Risk Reduction in Diabetes 
    2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
  • Join now to see all

Authored Content

  • ACC CardiaCast: Emerging Data in SGLT2 InhibitorsJune 2018
  • : An Analysis of CVD-REALJune 2018

Press Mentions

  • DELIVER Subanalysis ‘Seals Deal’ for Dapagliflozin in HF
    DELIVER Subanalysis ‘Seals Deal’ for Dapagliflozin in HFDecember 15th, 2022
  • How to Improve Diagnosis of HFpEF, Common in Diabetes
    How to Improve Diagnosis of HFpEF, Common in DiabetesOctober 3rd, 2022
  • Use Your Window into Heart Failure
    Use Your Window into Heart FailureJuly 27th, 2022
  • Join now to see all

Professional Memberships

Hospital Affiliations